Evidence map›Paper›PMID 21045729›Full record

ArticleJournal of hypertension2011

Independent regulation of α1 and α2 adrenergic receptor-mediated vasoconstriction in vivo.

Mordechai Muszkat, Daniel Kurnik, Gbenga G Sofowora, Alastair J J Wood, C Michael Stein

Abstract read
In one paragraph

Article in Journal of hypertension, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Genetic variation in the alphaThe pharmacogenomics journal · 2017
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mordechai MuszkatDivision of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 372332-6602, USA.
Daniel Kurnik
Gbenga G Sofowora
Alastair J J Wood
C Michael Stein
Vanderbilt University · US

Funding

YOHIMBINE AS A MODEL OF ORTHOSTATIC INTOLERANCEM01RR000095 · NCRR · VANDERBILT UNIVERSITY · PI MAY, JAMES M. · 1985 to 2008
$38.3M
Structural genomics of norepinephrine transportersP01HL056693 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BIAGGIONI, ITALO · 1997 to 2016
$30.8M
PHARMACOGENOMICS OF ARRHYTHMIA THERAPYU01HL065962 · NHLBI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2001 to 2009
$24.8M
THE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2009
$24.0M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
NCRR NIH HHS M01 RR000095NHLBI NIH HHS P01 HL056693NHLBI NIH HHS P01 HL56693NHLBI NIH HHS U01 HL065962NHLBI NIH HHS U01HL65962NHLBI NIH HHS U19 HL065962NIGMS NIH HHS GM 5MO1-RR00095NIGMS NIH HHS U01 GM061374NIGMS NIH HHS U01GM61374
6 · The paper itself

Abstract

backgroundVascular α1 and α2 adrenergic receptors mediate vasoconstriction and are major determinants of peripheral vascular tone. There is a wide variability in vasoconstrictor sensitivity to α1 and α2 adrenergic receptor agonists among individuals. In previous studies, this variability was not explained by identified α1 and α2 adrenergic receptor genetic variants. Thus, we hypothesized that adrenergic vasoconstrictor sensitivity is determined by shared constrictor mechanisms downstream of the individual receptors and that α1 and α2 adrenergic receptor-mediated vasoconstrictor sensitivity would therefore be correlated.

methodsDorsal hand vein responses to increasing doses of the α1 adrenergic receptor agonist phenylephrine (12-12 000 ng/min) and the α2 adrenergic receptor agonist dexmedetomidine (0.01-100 ng/min) were measured in healthy individuals using a linear variable differential transformer. From individual dose-response curves, we calculated the dose of phenylephrine and dexmedetomidine that produced 50% (ED50) of maximum venoconstriction (Emax) for each patient. We examined the correlation between phenylephrine and dexmedetomidine ED50 and Emax before and after adjustment for covariates (age, sex, ethnicity, BMI, blood pressure, heart rate, and baseline plasma norepinephrine concentrations).

resultsIn 62 patients (36 men, 34 African-American, 28 whites), the median ED50 for dexmedetomidine was 1.32 ng/min [interquartile range (IQR) 0.45-5.37 ng/min] and for phenylephrine 177.8 ng/min (IQR 40.7-436.5 ng/min). The Emax for phenylephrine was 90.8% (82.2-99.6%) and for dexmedetomidine 80.0% (64.7-95.2%). There was no correlation between individual sensitivities (ED50) to phenylephrine and dexmedetomidine, before and after adjustment for covariates (P > 0.30).

conclusionBoth phenylephrine and dexmedetomidine produce strong venoconstriction in the dorsal hand vein; however, there is no significant correlation between vascular sensitivity to an α1 and α2 adrenergic receptor agonist. These findings suggest the independent regulation of vascular α1 and α2 adrenergic receptor-mediated responses.

Indexed as

Adrenergic alpha-1 Receptor AgonistsAdrenergic alpha-2 Receptor AgonistsAdultDexmedetomidineDose-Response Relationship, DrugFemaleHandHumansMaleModels, CardiovascularPhenylephrineReceptors, Adrenergic, alpha-1Receptors, Adrenergic, alpha-2Signal TransductionVasoconstrictionYoung AdultAdrenergic alpha-1 Receptor AgonistsAdrenergic alpha-2 Receptor AgonistsDexmedetomidinePhenylephrineReceptors, Adrenergic, alpha-1Receptors, Adrenergic, alpha-2

Identifiers

PMID21045729
PMCPMC3012748
OpenAlexW1974756204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.